All OTC Ingredient TEAs Get Review Deadlines In Senate Draft Bill
This article was originally published in The Pink Sheet Daily
Executive Summary
Senate HELP Committee leaders’ draft bill expands on changes in the House’s Sunscreen Innovation Act by requiring deadlines for FDA review of all OTC ingredient TEAs. Chairman Harkin and other HELP members propose setting “reasonable” deadlines for TEA reviews.
You may also be interested in...
NDAC Input Sought On Sunscreen Ingredient Data Necessary For Approval
FDA’s Nonprescription Drugs Advisory Committee will meet Sept. 4-5 to discuss the scope and safety of testing necessary for OTC sunscreen ingredients. The announcement comes after FDA earlier this year rejected time and extent applications to add new sunscreen actives to the OTC monograph.
MHRA on herbals
"Using Herbal Medicines: Advice to Consumers" is a new guidance document issued July 27 that informs consumers about how to avoid low-quality products on the market, the UK's Medicines & Healthcare products Regulatory Agency announces. The document warns that "any medicine - herbal or otherwise - has the potential to have adverse effects," and states that the safe use of herbals "has not been established" in pregnant women, breastfeeding mothers, children or the elderly. MHRA also explains that products bearing a PL (product license) or THR (Traditional Herbal Registration) symbol on their product labels are regulated by the government, while products with no symbols have not been assessed by the agency. The guidance is being issued in the wake of MHRA's efforts to remove a number of questionable products from the market, including Real Herbs' supplement that was advertised to "inhibit the growth of tumor" and Rena Chinese Medical Center's capsule that claimed to have "strong effects in controlling HIV"...
J&J Consumer Sales Slip Even As Recalled Brands, Seasonal Items Reach Stores
J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.